Deal Watch: GSK Accelerates TCR Collaboration With Adaptimmune
Executive Summary
Merger combines troubled Avalanche's resources with Annapurna's brimming pipeline. Janssen sells its BetaLogic stem-cell IP to partner ViaCyte to hasten development of a stem cell therapeutic for diabetes.
You may also be interested in...
Deal Watch: Galenica Offers For Relypsa, But Other Suitors May Emerge
Allergan backs out of deal with Adamis for an EpiPen competitor just two months after signing the licensing deal, but before an up-front payment due date kicks in. AbCellera to team with MassBiologics to discover antibodies against drug-resistant Klebsiella infections.
Deal Watch: Amgen Takes Center Stage With Trio Of Transactions
The big biotech enters a collaboration in cancer immunotherapy and inflammation with Xencor, acquires Dutch biotech Dezima, and licenses a c-MET inhibitor to NantWorks. Also, Sun Pharma steps in to buy InSite Vision, which had been targeted by QLT.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.